Article summary
This analysis (n=17) of a double-blind randomised placebo-controlled trial and subsequent open-label study examined whether brain iron-sensitive MRI measures predicted response to repeated intravenous ketamine in people with treatment-resistant depression. Higher baseline measures in the right nucleus accumbens and left amygdala were associated with greater improvements in specific depressive symptoms.
Continue to the original publication for the complete article.